Allopurinol Does Not Affect eGFR in Chronic Kidney Disease
THURSDAY, June 25, 2020 -- Allopurinol does not affect estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease and does not result in a clinically meaningful benefit in kidney outcomes from serum urate reduction among... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 25, 2020 Category: Pharmaceuticals Source Type: news
University of Minnesota Medical School finds promising treatment to slow kidney disease doesn't prove out in clinical trial
(University of Minnesota Medical School) A new study from the University of Minnesota Medical School found that allopurinol, an inexpensive generic drug that reduces uric acid levels, did not show benefits in protecting from loss of filtering function in the kidney. The findings were recently published in the New England Journal of Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 25, 2020 Category: International Medicine & Public Health Source Type: news
AKI Associated With Febuxostat and Allopurinol AKI Associated With Febuxostat and Allopurinol
These two commonly used urate-lowering drugs may be associated with acute kidney injury in some patients. Find out what there is to know about this potential adverse event.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 7, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
PERL concludes reduced uric acid has no impact on kidney disease in type 1 diabetes
(Joslin Diabetes Center) Three years of sustained reductions of blood levels of uric acid with the generic drug allopurinol did not benefit type 1 diabetes patients with mild to moderate kidney disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 8, 2019 Category: International Medicine & Public Health Source Type: news
The Difficult Relationship Between Uric Acid and CVD The Difficult Relationship Between Uric Acid and CVD
While levels of serum uric acid have shown strong associations with the future risk of CVD, controversy about the cardiovascular safety of febuxostat compared with allopurinol persists.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 18, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Some May Be Vulnerable to Severe Skin Reaction While Using Gout Drug
TUESDAY, Oct. 1, 2019 -- Some gout patients with heart or kidney disease might be more susceptible to severe skin reactions while taking the gout medication allopurinol, researchers report. " Our findings suggest that heart disease, like chronic... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 1, 2019 Category: General Medicine Source Type: news
Heart Disease May Up Risk for Allopurinol-Linked Cutaneous AEs
MONDAY, Sept. 30, 2019 -- Heart disease is associated with an increased risk for hospital admission for allopurinol-associated severe cutaneous adverse reactions, according to a study published online Sept. 25 in CMAJ, the journal of the Canadian... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 30, 2019 Category: Pharmaceuticals Source Type: news
FDA Drug Safety Communication: FDA to evaluate increased risk of heart-related death and death from all causes with the gout medicine febuxostat (Uloric)
The U.S. Food and Drug Administration (FDA) is warning that preliminary results from a safety clinical trial show an increased risk of heart-related death with febuxostat (Uloric) compared to another gout medicine called allopurinol. We required the Uloric drug manufacturer, Takeda Pharmaceuticals, to conduct this safety study when we approved the medicine in 2009. Once we receive the final results from the manufacturer, we will conduct a comprehensive review and will update the public with any new information. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 22, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Allopurinol (Zyloprim, Aloprim)
Title: Allopurinol (Zyloprim, Aloprim)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 7/5/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 5, 2019 Category: Drugs & Pharmacology Source Type: news
Lesinurad/Allopurinol (DUZALLO ®) Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - April 15, 2019 Category: Drugs & Pharmacology Source Type: news
Unichem Labs gets USFDA nod to market Allopurinol tablets
The product will be commercialised from company's Ghaziabad plant, Unichem Laboratories said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 12, 2019 Category: Pharmaceuticals Source Type: news
FDA: Gout Drug Uloric Increases Risk of Death
FRIDAY, Feb. 22, 2019 -- The gout medicine Uloric (febuxostat) carries a higher risk of death than allopurinol, according to the U.S. Food and Drug Administration.
The agency said its in-depth review of results from a safety clinical trial found... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 22, 2019 Category: Pharmaceuticals Source Type: news
FDA Warns of Higher Risk for Death With Gout Drug Febuxostat FDA Warns of Higher Risk for Death With Gout Drug Febuxostat
Febuxostat should be reserved for patients with gout-related hyperuricemia for whom allopurinol has failed or who do not tolerate allopurinol, owing to an increased risk for death, the FDA says.News Alerts (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - February 22, 2019 Category: Internal Medicine Tags: Rheumatology News Alert Source Type: news
How Much Allopurinol Does It Take to Get to Target Urate? How Much Allopurinol Does It Take to Get to Target Urate?
A new study considers the optimal allopurinol dosing required to achieve target serum urate in patients with gout.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 6, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Allopurinol Linked to Reduced Risk for CKD Stage & #8805;3 in Gout
THURSDAY, Oct. 25, 2018 -- For patients with gout, allopurinol is associated with a reduced risk for developing chronic kidney disease stage ≥3, according to a study published online Oct. 8 in JAMA Internal Medicine.
Ana Beatriz Vargas-Santos,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 25, 2018 Category: Pharmaceuticals Source Type: news
